What changed for Sjogren's Syndrome
A plain English summary of what recently moved in the public data Voxsanity tracks for Sjogren's Syndrome. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 19 to 16 (-3)
- Trials on record 72 to 65 (-7)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Sjogren's Syndrome yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Sjogren's Syndrome that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT02962895 · results posted 29 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02962895) tested a medicine called VAY736 in people with Sjögren's syndrome, an autoimmune condition that causes dryness and fatigue, among other symptoms. In the first part of the trial (up to 24 weeks), 190 participants were randomly assigned to receive either a placebo (a dummy treatment) or one of three doses of VAY736 — 5 mg, 50 mg, or 300 mg. The trial used two main scoring tools to track participants over time: the ESSDAI, which is a doctor-assessed measure of disease activity scored from 0 to 123 (where lower is be...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04988087 · results posted 8 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04988087) enrolled 30 people across four groups. Twelve people received the study drug MHV370 (200mg) and 14 received a placebo (dummy treatment) for a condition called Sjögren's syndrome (SjS) — a disease that affects moisture-producing glands. A further 2 people received MHV370 and 2 received placebo for a condition called Mixed Connective Tissue Disease (MCTD). The trial ran for 24 weeks and was measuring changes in disease activity scores, fatigue, and how the drug moved through the body. Notably, a large number of par...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04093531 · results posted 25 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04093531) enrolled 12 people, all of whom received the drug ustekinumab. The trial was looking at Sjögren's syndrome — a condition that causes dryness, fatigue and pain — and ran for 24 weeks. Of the 12 people who started, 8 completed the trial and 4 did not. The main thing the trial was measuring was whether participants' self-reported symptoms — specifically dryness, fatigue and pain — changed over those 24 weeks, using a questionnaire called the ESSPRI (where 0 means no symptoms and 10 means the worst imaginable symptom...
-
NCT03445650 · results posted 9 February 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03445650) enrolled 11 people in total — 7 in the group using ADX-102 1% Topical Dermal Cream and 4 in the group using a vehicle cream (a cream without the active ingredient, used for comparison). Of those, 6 people in the ADX-102 group and 3 in the vehicle group completed the trial. The trial was measuring changes in skin scaling in people with ichthyosis (a condition that causes very dry, scaly skin) using a scoring tool called the Visual Index Ichthyosis Severity (VIIS) Scaling Score, which runs from 0 (least severe) to...
-
NCT04035668 · results posted 20 December 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04035668) enrolled 73 people with Sjögren's Syndrome — a condition that affects the immune system and causes dryness, pain, and fatigue. Participants were randomly assigned to one of three groups: remibrutinib taken twice daily (24 people), remibrutinib taken once daily (25 people), or a placebo (an inactive treatment, 24 people). The trial ran for 24 weeks and was primarily measuring changes in a standardised disease activity score called the ESSDAI, which rates how active Sjögren's Syndrome is across 12 body systems on a...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02402309 · results posted 13 December 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02402309) involved 12 people in total — 6 who used a cream called NS2 1% Dermatologic Cream applied to the skin, and 6 who used a vehicle cream (a comparison cream containing no active ingredient, sometimes called a placebo). All 12 participants completed the study with no one dropping out. The trial was primarily measuring whether participants experienced certain negative health events while using these creams. The reported data shows that the two main things being tracked were: (1) whether any participant experienced a...
-
NCT02257957 · results posted 24 August 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02257957) involved 30 people in total — 15 who received Platelet-Rich Plasma (PRP) eye drops and 15 who received standard care for dry eye. All 30 participants completed the study, with no drop-outs in either group. The trial was measuring changes in three things: the degree of surface damage to the eye (using a grading system called the Oxford Scale, scored from 0 to 5), the amount of moisture the eye produces (using a test called the Schirmer test, measured in millimetres), and how much dry eye symptoms affected daily li...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02193490 · results posted 5 November 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 47 people in total — 25 in the DNase group and 22 in the vehicle (comparison/control) group. Of those, 21 and 20 respectively completed the study. The trial was measuring changes in two main things over 8 weeks: the appearance of the eye's surface using a special dye called Rose Bengal (which highlights any damage to the cornea, the clear front part of the eye), and how much dry eye symptoms affected participants' daily lives, measured using a 12-question survey called the OSDI. A separate exploratory measure looked a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02066896 · results posted 3 August 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 66 people in total — 33 in a group that received active laser therapy and 33 in a group that received a sham (fake) version of the same laser therapy, meaning neither group knew which treatment they were getting. All 66 participants completed the trial with no drop-outs. The trial was measuring dry mouth symptoms, saliva flow, and a protein in saliva linked to a condition called Sjögren's syndrome — an illness where the immune system attacks the glands that make saliva and tears. The reported data shows that dry mout...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00344448 · results posted 21 December 2015
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called Raptiva compared to a placebo (a dummy treatment with no active ingredient) in people with a condition affecting saliva and tear production. The trial had two main phases — a 12-week blinded phase (where neither participants nor doctors knew who was getting which treatment) followed by an open-label phase (where everyone knew). A total of 10 people entered the screening stage, with 6 assigned to Raptiva and 3 to placebo going on to the blinded phase. By the end of the full trial, only a small number...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01647737 · results posted 18 March 2015
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 people in total — 30 in each group. One group used a green tea lozenge, while the other used a placebo (a dummy lozenge with no active ingredient). The trial was looking at people experiencing xerostomia, which simply means a dry mouth condition, and it measured whether saliva flow changed over the course of the study. Of those who started, 26 people in the green tea lozenge group and 25 in the placebo group completed the trial. The reported data shows that the trial measured saliva flow in millilitres per minute...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a small amount of public research funding is currently being directed toward Sjogren's Syndrome, and encouragingly, that funding has been rising year on year. This upward trend suggests that researchers and funding bodies are paying increasing attention to the condition, which is a positive signal for patients hoping to see more scientific progress over time. Rising...
See the full Sjogren's Syndrome page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.